Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 6th January 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer launches new purification technology for Ingelvac CircoFLEX®
Drug firm Boehringer Ingelheim has announced new purification technology for Ingelvac CircoFLEX®.
Vaccine to be launched in all EU countries in January 2020

Pharmaceutical firm Boehringer Ingelheim has announced a new and proprietary purification process for its swine vaccine, Ingelvac CircoFLEX®.

Ingelvac CircoFLEX® was the first PCV2 (porcine circovirus type 2) that could be mixed with an M hyo vaccine to address two critical swine pathogens in a single dose. Considered to be the most revolutionary PCV2 vaccines on the market, it provides effective control of circovirus-associated disease in pigs aged three weeks and older.

The new diafiltration process, named DiaTEC, removes residual cell media components from the virus-like particles (VLPs) to obtain highly immunogenic and non-virucidal vaccine.

A press release reads: “With DiaTEC, a new and proprietary diafiltration technology, Ingelvac CircoFLEX® becomes the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed on farm.”

Eva Joras, global brand manager at Boehringer Ingelheim, said: “I am really proud that we continuously invest in our research and development to further improve our leading products to address our customers’ needs.”

Ingelvac CircoFLEX®, manufactured with the new technology, will be launched in several different packaging sizes in all EU countries in January 2020. 

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.